This episode discusses patient access to AveXis' gene therapy Zolgensma from Orsini Healthcare, US based specialty pharmacy's perspective. The senior team at Orsini provide insight on their experience of Zolgensma access including key manufacturer criteria, payer landscape along with challenges and lessons learnt.
Presenter: Aparna Krishnan
Contributors: Dave Frobel, Senior Vice President, Trade & Tom Shaughnessy, Senior Vice President, Health Plans
Producer: Aparna Krishnan
About Orsini Healthcare: Founded in 2009, Orsini is a leading independent specialty pharmacy focused on rare conditions and gene therapies. Orsini was one of the first specialty pharmacies to provide Zolgensma, the first gene therapy for Spinal Muscular Atrophy. Today, Orsini has access to 40 limited distribution drugs, has more than 525 direct payor contracts and is recognized as a reimbursement expert in managing both medical and pharmacy benefits.
Weekly Roundup: August 16, 2018
Weekly Roundup: August 9, 2018
Weekly Roundup: August 2, 2018
Weekly Roundup: July 26, 2018
Weekly Roundup: July 17, 2018
Weekly Roundup: July 11, 2018
Weekly Roundup: July 4, 2018
Weekly Roundup: June 26, 2018
Weekly Roundup: June 19, 2018
Weekly Roundup: June 12, 2018
Weekly Roundup: June 5, 2018
Weekly Roundup: May 31, 2018
Create your
podcast in
minutes
It is Free
DNA Today: A Genetics Podcast
Museum of the Missing
Strange by Nature Podcast
Sasquatch Chronicles
Hidden Brain